Results 241 to 250 of about 345,374 (311)

Lupus Anticoagulant Testing

2013
Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus ...
Karen, Moffat, Anne, Raby, Mark, Crowther   +2 more
openaire   +2 more sources

Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI)

Lupus, 2012
Results for lupus anticoagulant (LA) are expressed as ratio of patient-to-normal clotting times (LA-ratio) according to the equation LA-ratio = (PatientClotting time/NormalClotting time). However, numerical results vary according to the method used for testing, thus making difficult the between-method and between-laboratory comparison of results.
Tripodi A, Chantarangkul V, PENGO, VITTORIO   +2 more
openaire   +2 more sources

The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants

Clinical Chemistry and Laboratory Medicine, 2019
Background Direct oral anticoagulants (DOACs) cause false positive lupus anticoagulant (LA) results. We assessed the impact of DOAC-Stop, reversing in vitro effects of DOACs, on LA testing in anticoagulated patients.
M. Ząbczyk, M. Kopytek, J. Natorska, A. Undas   +3 more
semanticscholar   +1 more source

Lupus anticoagulant in pregnancy

BJOG: An International Journal of Obstetrics & Gynaecology, 1984
summaryIn a group of 10 women with circulating lupus anticoagulant 25 intrauterine deaths were previously documented in the nine multigravidae. The presence of lupus anticoagulant activity was confirmed by showing prolongation of the activated partial thromboplastin time and kaolin clotting time with failure of correction of the prolongation on ...
W F, Lubbe, W S, Butler, S J, Palmer, G C, Liggins   +3 more
openaire   +4 more sources

Procainamide-Induced Lupus Anticoagulant

Southern Medical Journal, 1988
The lupus anticoagulant, with or without other symptoms or signs of lupus, has been described in patients taking procainamide. Screening all such patients for the presence of these anticoagulants may be warranted (despite the rarity of episodes of bleeding) in view of the potentially increased risk of thrombotic events in patients who may already be ...
M R, Heyman, R H, Flores, B B, Edelman, N H, Carliner   +3 more
openaire   +2 more sources

Lupus anticoagulant in myelofibrosis

The American Journal of the Medical Sciences, 1976
A patient with myelofibrosis who also demonstrates a lupus anticoagulant is reported. The presence of a circulating anticoagulant adds to the list of potential hemorrhagic diatheses in myelofibrosis and also demonstrates myelofibrosis to involve a system that may be separate from the myeloid elements of the bone marrow.
B, Bernhardt, M, Valletta
openaire   +2 more sources

Lupus Anticoagulant and Stroke

Archives of Neurology, 1987
To the Editor. —Tabachnik-Schor and Lipton's 1 recent report of a case of nonvasculitic cerebral infarction associated with a lupuslike anticoagulant (LA) suggests that their case is the first without "other causes of vasculopathy." Several features of their patient's case do not appear to support their conclusion. Their patient's skin biopsy specimen
S R, Levine, K M, Welch
openaire   +2 more sources

Lupus anticoagulant and pregnancy

American Journal of Obstetrics and Gynecology, 1985
A subset of women with a high rate of fetal wastage is identifiable among those with serologic but not necessarily clinical evidence of connective tissue disease. The presence of lupus anticoagulant in the plasma of a pregnant woman serves as a marker for a high rate of fetal wastage and risk of thrombosis. Lupus anticoagulant is best identified by the
W F, Lubbe, G C, Liggins
openaire   +2 more sources

Testing for Lupus Anticoagulants

Seminars in Thrombosis and Hemostasis, 2022
AbstractLupus anticoagulant (LA) is one of the three criteria antiphospholipid antibodies (aPLs) employed in classification, and by default diagnosis, of antiphospholipid syndrome (APS). Detection of LA is not via calibrated assays but is based on functional behavior of the antibodies in a medley of coagulation assays.
openaire   +2 more sources

[Lupus anticoagulant].

Rinsho byori. The Japanese journal of clinical pathology, 1993
Lupus anticoagulant (LAC) is an acquired inhibitor of prothrombin activator complex, which probably interferes with the phospholipid portion. Characteristically, LAC prolongs the partial prothrombin time, but only slightly prolongs the prothrombin time. It is a paradoxical fact that LAC is characterized by thrombosis.
A, Yoshida, K, Morozumi
openaire   +1 more source